MedTrace Logo

Beat AML Core Study

NCT02927106 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2020-08-05

No results posted yet for this study

Summary

In this study, DNA sequencing, computational biology modeling, and ex vivo drug sensitivity assays will be utilized to define clinically relevant gene mutations and identify potential therapeutics for patients with acute myeloid leukemia (AML).

Conditions

Sponsors & Collaborators

  • Oregon Health and Science University

    collaborator OTHER

  • Cellworks Group Inc.

    collaborator INDUSTRY

  • The Leukemia and Lymphoma Society

    collaborator OTHER

  • University of Florida

    lead OTHER

Principal Investigators

  • Christopher R. Cogle, MD · University of Florida

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2020-07-29
Completion
2020-07-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02927106 on ClinicalTrials.gov